Journal
VASCULAR
Volume 29, Issue 1, Pages 61-68Publisher
SAGE PUBLICATIONS LTD
DOI: 10.1177/1708538120937955
Keywords
Carotid endarterectomy; 30-day readmission; complications
Categories
Funding
- Agency for Healthcare Research and Policy [R24HS022140]
Ask authors/readers for more resources
This study assessed the 30-day all-cause readmissions after carotid endarterectomy. Factors associated with readmission included end-stage renal disease, bleeding or hematoma, procedural complications, bronchodilator use, increased comorbidity burden, and electrolyte abnormalities. Efforts to reduce preventable physician-driven complications, such as protamine utilization, are crucial in lowering readmission rates.
Objective The current study evaluated all-cause 30-day readmissions after carotid endarterectomy. Methods Patients undergoing carotid endarterectomy were selected from the Cerner Health Facts (R) database using ICD-9-CM procedure codes from their index admission. Readmission within 30 days of discharge was determined. Chi-square analysis determined characteristics of the index admission (demographics, diagnoses, postoperative medications, and laboratory results) associated with readmission. Multivariate logistic regression models were used to identify characteristics independently associated with readmission. Results In total, 5257 patients undergoing elective carotid endarterectomy were identified. Readmission within 30 days was 3.1%. After multivariable adjustment, readmission was associated with end-stage renal disease (OR: 3.21, 95% CI: 1.01-10.2), hemorrhage or hematoma (OR: 2.34, 95% CI: 1.15-4.77), procedural complications (OR: 3.07, 95% CI: 1.24-7.57), use of bronchodilators (OR: 1.48, 95% CI: 1.03-2.11), increased Charlson index scores (OR: 1.22, 95% CI: 1.08-1.38), and electrolyte abnormalities (hyponatremia < 135 mEq/L (OR: 1.69, 95% CI: 1.07-2.67) and hypokalemia less than 3.7 mEq/L (OR: 2.26, 95% CI: 1.03-4.98)). Conclusions Factors associated with readmission following carotid endarterectomy included younger age, increased comorbidity burden, end-stage renal disease, electrolyte disorders, the use of bronchodilators, and complications including bleeding (hemorrhage or hematoma). Of note, in this real-world study, only 40% of the patients received protamine, despite evidence-based literature demonstrating the reduced risk of bleeding complications. As healthcare moves towards quality of care-driven reimbursement, physician modifiable targets such as protamine utilization to reduce bleeding are greatly needed to reduce readmission, and failure to reduce preventable physician-driven complications after carotid interventions may be associated with decreased reimbursement.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available